Aggressive Stock Portfolio: 12 Stocks Picked by Hedge Funds

8. argenx SE (NASDAQ:ARGX) 

3-Year Average Revenue Growth: 62.15%

Number of Hedge Fund Holders: 47

argenx SE (NASDAQ:ARGX) works as a biotech company that develops cutting-edge therapies for autoimmune diseases across the US, Europe, and Asia. The top candidate for the company is efgartigimod, which has won approval for several conditions, including myasthenia gravis and chronic inflammatory demyelinating polyneuropathy (CIDP). It is also pushing forward with other promising products like empasiprubart and ARGX-119 for a range of neuromuscular and inflammatory disorders.

argenx SE (NASDAQ:ARGX) had solid finances in Q4 2024, beating past earnings expectations with an EPS of $11.79 versus the predicted $0.98. While net product sales hit $737 million for the quarter, surging 29% from the prior, full-year sales reached $2.2 billion, almost double last year’s figures. The company made an operating profit of $103 million in Q4, with a full-year net profit of $833 million, backed by a one-time tax benefit of $725 million. Moreover, argenx maintained impressive 90% gross margins, though operational costs soared due to Research and Development investments.

argenx SE (NASDAQ:ARGX) keeps further expanding its commercial portfolio to boost its growth in 2025. Efforts include expanding labels, hitting regulatory milestones, and launching innovations like its prefilled syringe for self-administration. The company’s robust pipeline includes 10 Phase III and 10 proof-of-concept studies, setting argenx up for long-term success in treating autoimmune diseases.

In the future, 2025 argenx SE (NASDAQ:ARGX) expects 2025 to be its first profitable year, driven by strong commercial execution and R&D progress. The company is working to make treatments more accessible with strategic investments, planning to spend about $2.5 billion on operating expenses to fuel innovation. With this mix of revenue growth and strong earnings, argenx is positioned as a top pick in our stock portfolio.